FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA 483 Shows GMP Troubles at Plant Making Eylea

[ Price : $8.95]

A new Form FDA-483 cites significant GMP issues at the plant that makes Regenerons Eylea HD (aflibercept), delaying review of two ...

FDA Clears Signos OTC Glucose Monitor

[ Price : $8.95]

FDA clears a Signos 510(k) for what the company says is the first over-the-counter glucose monitoring system designed specifically...

FDA Moves to Daily Drug Adverse Event Data

[ Price : $8.95]

FDA is now publishing drug safety data on a daily basis, a shift the agency says will give the public faster access to information...

Device Dental Bone Graft Study Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for 510(k) animal studies for dental bone grafting material devices.

Oncology Trial Overall Survival Assessment Guide

[ Price : $8.95]

FDA publishes a draft guidance with recommendations for approaches to assessing overall survival in oncology clinical trials.

Stealth Gets Expedited Review on NDA Resubmission

[ Price : $8.95]

FDA accepts for review a Stealth BioTherapeutics NDA resubmission for elamipretide for treating Barth syndrome, with the agency ag...

Nicox Plans NDA for Glaucoma Drug

[ Price : $8.95]

Nicox plans an NDA early next year after new data from its DENALI Phase 3 study of glaucoma therapy NCX 470 showed promising resul...

Gaps Seen in Dementia AI Device Transparency

[ Price : $8.95]

Researchers call for greater transparency of artificial intelligence/machine learning training and validation datasets in devices ...

FDA OKs Ionis Hereditary Angioedema Drug

[ Price : $8.95]

FDA approves an Ionis Pharmaceuticals NDA for Dawnzera (donidalorsen) as the first RNA-targeted prophylactic treatment for heredit...

Rinvoq Meets Endpoints in Alopecia Trial

[ Price : $8.95]

AbbVie reports that its JAK inhibitor Rinvoq (upadacitinib) met primary and secondary endpoints in a pivotal Phase 3 study testing...